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Abstract 
Background: The painDETECT questionnaire (PD-Q) has been used as a tool to 
characterize sensory abnormalities in patients with persistent pain. This study 
investigated whether the self-reported sensory descriptors of patients with painful 
cervical radiculopathy (CxRAD) and patients with fibromyalgia (FM), as characterized 
by responses to verbal sensory descriptors from PD-Q (sensitivity to light touch, cold, 
heat, slight pressure, feeling of numbness in the main area of pain), were associated with 
the corresponding sensory parameters as demonstrated by quantitative sensory testing 
(QST).  
Methods: Twenty-three patients with CxRAD (eight women, 46.3 ± 9.6 years) and 22 
patients with FM (20 women, 46.1 ± 11.5 years) completed the PD-Q. Standardized QST 
of dynamic mechanical allodynia, cold and heat pain thresholds, pressure pain thresholds, 
mechanical and vibration detection thresholds was recorded from the maximal pain area. 
Comparative QST data from 31 age-matched healthy controls (HCs; 15 women) were 
obtained.  
Results: Patients with CxRAD demonstrated a match between their self-reported 
descriptors and QST parameters for all sensory parameters except for sensitivity to light 
touch, and these matches were statistically significant compared to HC data (p ≤ 0.006). 
The FM group demonstrated discrepancies between the PD-Q and QST sensory 
phenotypes for all sensory descriptors, indicating that the self-reported sensory 
descriptors did not consistently match the QST parameters (p = ≤ 0.017).  
Conclusion: Clinicians and researchers should be cautious about relying on PD-Q as a 




The traditional approach to classification and management of musculoskeletal and 
neuropathic pain (NeP) according to the aetiological condition has its limitations 
(Jensen and Baron, 2003; Baron, 2006). A mechanism, or symptom based 
classification approach, (Jensen and Baron, 2003; Baron, 2006) has been proposed. 
This approach is based on the hypothesis that different clinical signs and symptoms 
reflect different underlying pathophysiological mechanisms of pain generation 
(Hansson, 2002; Jensen and Baron, 2003), with the ultimate aim to target treatment to 
the underlying pain mechanisms. The assessment of symptoms can be attained by 
means of questionnaires such as the Neuropathic Pain Symptom Inventory (NPSI) 
(Bouhassira et al., 2004; Attal et al., 2008) and the painDETECT questionnaire (PD-
Q) (Freynhagen et al., 2006; Baron et al., 2009; Mahn et al., 2011) and signs by 
quantitative sensory testing (QST) (Haanpää et al., 2011). 
 
The PD-Q was originally developed and validated as a screening tool to identify 
patients with likely NeP (Freynhagen et al., 2006), and has been employed in this 
capacity in various patient populations (Steegers et al., 2008; Gwilym et al., 2009; 
Jespersen et al., 2010). Recently it has also been used in large surveys, as a tool to 
identify somatosensory profiles in patients with lumbar radiculopathy/radicular pain 
(Mahn et al., 2011), in patients with diabetic neuropathy and postherpetic neuralgia 
(Baron et al., 2009) and in patients with fibromyalgia (FM) (Rehm et al., 2010; 
Koroschetz et al., 2011). Based on the responses to verbal sensory descriptors in PD-
Q and results of cluster analyses, these latter four studies were able to demonstrate 
sub-groups of patients with distinct symptom profiles. No study to date has shown 
symptom profiles for patients with CxRAD, using the PD-Q. 
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The PD-Q contains questions relating to evoked pain (light touch, pressure, cold/heat) 
and numbness. Whilst a correlation between self-reported responses to evoked pain 
(brushing, pressure, cold) and clinical sensory testing has been demonstrated for the 
NPSI questionnaire (Attal et al., 2008), no study to date has assessed the criterion-
related validity for such parameters of PD-Q. A comparison of responses to PD-Q 
with more objective measurements like standardised QST may substantiate the 
validity of the questionnaire. QST is a valuable tool to obtain reliable quantitative 
measures of the presence of positive sensory signs such as allodynia and mechanical 
and thermal hyperalgesia as well as negative signs (sensory loss) (Rolke et al., 2006a; 
Rolke et al., 2006b; Hansson et al., 2007; Cruccu et al., 2010; Maier et al., 2010). 
 
The aim of our study was to investigate whether the self-reported sensory descriptors 
for evoked pain and numbness of patients with painful CxRAD and of patients with 
FM, as indicated by responses to verbal sensory descriptors items of PD-Q, were 
associated with their corresponding sensory parameter as demonstrated by QST, using 





2.1. Study population 
This study included patients with painful CxRAD (n = 23), patients with FM (n = 22) 
and age matched healthy controls (HC) (n = 31) (Table 1). Patients were recruited 
from general private physiotherapy, medical, and neurosurgery practices; 
physiotherapy and pain management departments at five local hospitals; a 
neurosurgery outpatient department; a neurosurgery triage clinic at a large 
metropolitan hospital; from the local community via radio and newspaper advertising 
and from FM support groups. The study protocol and recruitment procedures were 
approved by the local Ethics Committee of all participating institutions and adhered to 
the ethical guidelines of the Declaration of Helsinki. Informed consent was obtained 
from each subject prior to participation. 
 
The inclusion criteria for patients with CxRAD were: unilateral pain distribution 
consistent with specific radicular distributions (C6/C7), symptom duration of 3 to 18 
months, pain intensity ≥ 2 on a visual analogue scale (VAS), signs of C6 or C7 nerve 
root dysfunction such as sensory impairment and motor impairment (either myotomal 
weakness and/or absent or diminished reflexes) and a demonstrable clinically relevant 
abnormality on imaging studies (Treede et al., 2008; Bono et al., 2011) indicating 
compromise of the exiting nerve root at the relevant spinal level. Exclusion criteria 
were: evidence of medical or metabolic disease, a history of cardiovascular disease, 
neurological or psychiatric disease and an insufficient level of English. Depending on 
the mode of recruitment, some of the potential subjects underwent an initial phone 
screening examination to ascertain they satisfied the inclusion and exclusion criteria. 
Prior to inclusion into the study, all patients underwent a comprehensive clinical 
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examination in order to ascertain they met the inclusion criteria. As no gold standard 
exists for the diagnosis of painful cervical radiculopathy, the consensus of two clinical 
experts (a Fellow-trained Neurosurgeon and a Fellow-qualified Specialist in 
Musculoskeletal Physiotherapy) was used to verify the diagnosis, as consistent with a 
previous study (Freynhagen et al., 2008). Using a blinded design, both experts 
reviewed the patient’s clinical records, including the findings of the clinical 
examination and available investigations. Where there was not consensus between the 
experts and clinical examiner, subjects were excluded from the data analyses.  
 
Patients with FM underwent an initial phone screening examination to ascertain they 
fulfilled the inclusion and exclusion criteria. The diagnostic criteria for FM according 
to the 1990 American College of Rheumatology (ACR) (Wolfe et al., 1990) were 
used as inclusion criteria and were current at the time of recruitment. These criteria 
include widespread pain of at least 3 months duration in combination with tenderness 
at 11 or more of 18 specific anatomical sites. Although new diagnostic criteria now 
exist (Wolfe et al., 2010), the clinical profile of our FM group appears to also 
correspond with these new guidelines (Table 1). The exclusion criteria were the same 
as for the radiculopathy group. Of the participating 22 patients, 9 patients had been 
diagnosed with FM by a rheumatologist, 4 patients by a medical specialist (the patient 
could not remember what type of specialist), 8 patients by their general practitioner 
by exclusion (negative blood tests) and positive tender point count, and in one patient 
the origin of the diagnosis was not recorded. Prior to participation, tender point count 
was verified by means of a pressure algometer (probe size 1cm2) (Somedic AB, 
Farsta, Sweden), and assessing nine paired points as defined by the ACR Criteria 
(Wolfe et al., 1990) and two control points (at the centre of the right forearm and the 
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right thumb nail). The algometer was placed on the examination site, and pressure 
was gradually increased by 1 kg/s. The participants were asked to press a button when 
the sensation at the examination site changed from pressure to pain. Pressure testing 
was stopped at that moment and the result recorded as positive if maximal pressure 
was ≤ 4kg. If no pain was elicited at ≤ 4kg, the test results were recorded as negative. 
The average number of tender point ratings of pain was 19 (+/- 0.9) from the possible 
22. The patient’s clinical history was taken, including pain location on a body chart 
and identification of the main pain area nominated as the site to be tested by QST. All 
patients were requested to refrain from non–steroidal anti-inflammatory drugs and 
analgesics on the day of examination. 
 
HC were recruited from the local community and were excluded if they had a history 
of current pain or a chronic pain condition or fulfilled any of the exclusion criteria for 
the patients, including taking medications which influence pain perception. 
 
2.2. Questionnaires 
All patients completed the PD-Q. The PD-Q is a self–reported tool consisting of 
seven weighted sensory descriptor items, plus one item relating to temporal pain 
characteristics and one item relating to spatial pain characteristics. The questionnaire 
was originally designed to identify NeP components specifically in low back pain 
patients with and without referred pain (Freynhagen et al., 2006). The PD-Q was 
developed and validated in 392 German patients with clinically diagnosed pain of 
predominantly either nociceptive or neuropathic origin and demonstrated a sensitivity 
of 85% and specificity of 80%. The Cronbach’s alpha as measure of internal 
consistency of the seven weighted sensory descriptors was 0.83 (Freynhagen et al., 
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2006). Reliability was not assessed in that study as the authors considered this 
ethically and scientifically unjustifiable (Freynhagen et al., 2006). Reliability of the 
Swedish versions of PD-Q assessed in 40 patients with spinal cord injury was 
moderate (kappa coefficient 0.59) and sensitivity to identify NeP was 68% and 
specificity 83% (Hallström and Norrbrink, 2011). A validation study of the Spanish 
PD-Q in 221 patients with various etiologies (peripheral and central NeP and 
nociceptive pain disorders) demonstrated 81.2% sensitivity and specificity with an 
intraclass correlation coefficient of 0.934 for reliability measured over 1-2 days (De 
Andrés et al., 2012). To our knowledge, no reliability and validity data exist on the 
English version of PD-Q.  
 
The following questionnaires were employed in order to characterise the patients and 
HC group and to capture the multidimensional aspects of pain as recommended by the 
IMMPACT guidelines (Dworkin et al., 2012). Patients and HC subjects completed the 
short form-36 health questionnaire (SF-36) to assess quality of life (Ware, 2000) and 
the Hospital Anxiety and Depression Scale (HADS) to screen for the presence of 
psychological factors (Zigmond and Snaith, 1983). Individual scores for anxiety and 
depression are generated with a maximum score of 21 for each parameter. Scores of ≤ 
10 for each are considered within normal range. In addition, sleep quality over the last 
week was rated by all subjects on a 100-cm VAS with the end points 0 cm (good 
sleep) and 10 cm (bad sleep) (Hurtig et al., 2001). Sleep disturbance was assessed by 
asking whether the subject awakened tired or non-refreshed; fatigue was assessed by 
asking: “Are you fatigued?” (Wolfe et al., 1990). Both questions allowed for answers: 
“never”, “seldom”, “often or usually”, “always”. “Often or usually” or “always” was 
scored as positive, and other replies as negative. In all patients, average pain intensity 
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over the last week was determined with a VAS with the end points 0 cm (no pain) and 
10 cm (maximum tolerable pain) (Jensen et al., 1989). The strongest and average pain 
intensity over the last four weeks were documented on a numeric rating scale (NRS) 
as part of the PD-Q (0 = no pain, 10 = maximum pain). All questionnaires were 
administered before the QST testing was performed. 
 
2.3. Quantitative sensory testing 
Standardised QST measures were recorded according to the QST protocol of the 
German Research Network on Neuropathic Pain (DFNS) (Rolke et al., 2006a; Rolke 
et al., 2006b). This protocol comprises a battery of standardised tests in the following 
order: thermal detection thresholds for the perception of cold and warm and 
paradoxical heat sensation, cold and heat pain thresholds (CPT, HPT), mechanical 
detection threshold for touch (MDT), mechanical pain threshold for pinprick, a 
stimulus-response-function for pinprick sensitivity and dynamic mechanical allodynia 
(DMA), wind-up ratio to repetitive pinprick stimuli, mechanical detection thresholds 
for vibration (VDT) and pain thresholds to blunt pressure (PPT). Good test/retest- and 
inter-observer-reliability of this protocol has been demonstrated (Geber et al., 2011). 
In our laboratory the Intraclass-Correlation Coefficients (ICC) for triplicate 
measurements on the same day for all measurements of interest were > 0.9 (ICC [95% 
CI] for CPT 0.94 [0.85 - 0.98]; HPT 0.94, [0.85 - 0.98]; VDT 0.93 [0.84 - 0.98]; PPT 
0.92 [0.80 - 0.97]). Measurements were taken from the main pain area, as nominated 
by the patients (upper trapezius muscle n = 18; paravertebral cervical spine n = 4, 
paravertebral thoracic spine n = 11; above and below spine scapula n = 3; upper arm n 
= 6; forearm n = 2, just above the elbow n = 1). HC reference data from a parallel 
study of ours were used for comparison. Measurements in the upper trapezius muscle 
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had been obtained in 26 HC and measurements in all other pain areas in 8 HC, the 
latter including 3 HC in the upper trapezius group, consistent with established 
methodology in a previous QST study (Blankenburg et al., 2010). QST was conducted 
on each subject by the same investigator in a laboratory with a constant room 
temperature. The investigator was not aware of the patient’s responses to the PD-Q. 
The full QST protocol as outlined above was performed on all subjects as part of 
another concurrent study. However, for the purpose of this study, only the following 
recordings were used to assess the patient’s responses to the PD-Q. 
 
PainDETECT question: Is light touching (clothing, a blanket) in this area painful? 
QST test: Pain in response to stroking light touch (DMA) was assessed using a cotton 
wisp (3 mN), a cotton wool tip fixed to an elastic strip (100 mN) and a brush exerting 
a force of 200-400 mN. Subjects were asked to give a pain rating for each stimulus on 
a NRS (0 = no pain, 100 = most intense pain imaginable). This assessment forms part 
of the stimulus-response-function for pinprick sensitivity and DMA. Pinprick and 
light stroking applications were performed five times in a randomised sequence. 
DMA was calculated as the geometric mean of all numerical ratings across all three 
different types of light touch stimuli. 
 
PainDETECT question: Is cold or heat (bath water) in this area occasionally painful? 
QST test: CPT and HPT were measured using the MSA Thermotest system (Somedic 
AB, Farsta, Sweden). All thresholds were obtained with ramped stimuli (1° C/s) 
which were terminated when the subject pressed a button. The baseline temperature 
was set at 32˚C; cut-off temperatures were 5˚C and 50˚C. The mean threshold 
temperature of three consecutive measurements was calculated. 
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PainDETECT question: Do you suffer from a sensation of numbness in the areas that 
you marked?  
QST test: The MDT was measured with a standardised set of modified von Frey hairs 
(Optihari2-Set, Marstock Nervtest, Germany) that exert forces upon bending between 
0.25 and 512 mN. The final threshold was the geometric mean of five series of 
ascending and descending stimulus intensities (Rolke et al., 2006b). A Rydel-Seiffer 
tuning fork (64Hz, 8/8 scale) was used to obtain the vibration detection threshold 
(VDT). VDT was measured over bony prominences unless the maximal pain area did 
not exhibit a bony surface (n = 11), in which case, measurements were taken over 
adjacent soft tissue. The threshold was determined as a disappearance threshold with 
three stimulus repetitions (Rolke et al., 2006b). 
 
PainDETECT question: Does slight pressure in this area, e.g., with a finger, trigger 
pain?  
QST test: PPTs were recorded using a pressure algometer with a probe size of 1cm2 
and application rate of 50 kPa/s (Somedic AB, Farsta, Sweden). The subjects were 
asked to push a button when the sensation changed from one of pressure alone to one 
of pressure and pain. Triplicate recordings were taken and the mean values used for 
analysis.  
 
2.4. Statistical analysis 
Data were analysed using the statistical package SPSS vs 17. Each question of the 
PD-Q has five possible scores listed as: never = 0; hardly noticed = 1; slightly = 2; 
moderately = 3; strongly = 4; very strongly = 5 (Freynhagen et al., 2006). As no 
criteria are currently available to indicate validated cut-offs defining what constitutes 
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a clinically relevant sensory disturbance, we chose the score “moderately” (≥ 3) as our 
cut-off score and defined this as a positive response and scores of < 3 as a negative 
response. Other researchers defined a clinically relevant sensory disturbance if 
patients marked a score > 3 (strongly and very strongly) (Baron et al., 2009; Amris et 
al., 2010; Rehm et al., 2010; Koroschetz et al., 2011; Mahn et al., 2011). 
Consequently, we re-analysed our data using the cut-off scores >3. Results are 
reported as supplementary material (Table S4, S5).  
 
QST data were log-transformed prior to statistical analysis except HPT and VDT 
which were normally distributed as raw data (Rolke et al., 2006a; Rolke et al., 2006b). 
To compare and illustrate the patients’ QST data with control data, independently of 
the different units of measurement, the log data of CPT, MDT and PPT and raw data 
of HPT and VDT were z-transformed using the following expression: Z-score = 
(Mean single proband – Mean healthy controls)/SD healthy controls (Rolke et al., 2006b). Z-values 
were calculated based on the included HC group data. To assess any difference in z-
score QST parameters between positive and negative responders compared to healthy 
control data, a univariate analysis was performed for each patient group. Post hoc 
comparisons were calculated using Bonferroni-post hoc tests for  
(i) all patients giving positive responses and matched HC,  
(ii) all patients giving negative responses and HC  
(iii) patients giving positive responses and patients giving negative responses. 
Patient subgroups with less than 4 patients were not included in the univariate 
analysis. In this case, an independent T-test was used to analyse differences between 
the HC group and the remaining larger patient subgroup. The measurements of CPT, 
HPT and PPT in our patients were significantly lower in females than males (p 
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<0.001), consistent with previous reports (Rolke et al., 2006a), hence gender was 
included in the model for analyses of these QST parameters. Measurements of MDT 
and VDT were not affected by gender in our study. 
 
Data are presented as mean and standard deviation (SD). Age and sleep quality were 
compared between groups using one-way ANOVA. Post hoc comparisons were 
calculated using LSD-post hoc tests. The frequency of sleep disturbances was 
determined using Fisher’s exact test. Anxiety and depression scores and the physical 
and mental components of the SF-36 were compared between groups using the 
Kruskal-Wallis Test. If there was a difference between groups, further pairwise 
analyses were performed using the Mann-Whitney-U Test. Symptom duration and 
pain intensity were compared between patient groups using an independent-samples 




3.1. Clinical profiles 
A summary of the demographics is presented for each group in Table 1. Both patient 
groups had significantly poorer sleep quality compared to HC and more frequently 
reported signs of increased sleep disturbance and fatigue. Patient groups also had 
significantly higher anxiety and depression scores on the HADS than HC. 
Nonetheless, depression scores were within the normal range for over 85% of patients 
in both groups. Anxiety scores were within the normal range in 91% of patients with 
CxRAD, but in only 32% of patients with FM. SF-36 physical and mental component 
summary scores were significantly lower than in HC.  
 
3.2. Sensory phenotypes 
The z-score QST sensory profiles for CPT, HPT, MDT, VDT and PPT in patients 
with CxRAD are illustrated in Figure 1. There was a significant gain in cold, heat and 
pressure sensitivity in those patients with CxRAD who indicated being sensitive to 
these QST parameters and a sensory loss in patients who indicated feeling numbness. 
QST parameters of patients responding negative to the PD-Q questions were within 
one SD of the HC data.  
 
Figures 1 and 2 to be inserted here or after next sentence 
 
The z-score QST sensory profiles of patients with FM are illustrated in Figure 2. All 
patients with FM demonstrated a significant gain in cold, heat and pressure 




3.2.1. Patients with cervical radiculopathy 
Sensitivity to light touch 
The PD-Q report indicated sensitivity to light touch in four patients with CxRAD 
(Table 2), and one of these patients demonstrated DMA on QST testing. Nineteen 
patients reported not being sensitive to light touch on PD-Q. None of these 
demonstrated DMA and no HC demonstrated DMA.  
 
Sensitivity to cold/heat 
Patients responding being sensitive to cold or heat demonstrated a significantly 
increased sensitivity to cold and heat (CPT: p = 0.001; HPT: p = 0.006) compared to 
HC subjects (Table 2). Patients who indicated not being sensitive to cold/heat did not 
differ in their pain thresholds when compared to HC. Patients indicating being 
sensitive to heat demonstrated a lowered HPT compared to patients not being 
sensitive to heat (p = 0.018). 
 
Sensation of numbness 
Patients who indicated feeling numbness in the area of pain demonstrated a loss of 
sensation, manifesting as a significantly elevated MDT (p = 0.004) and VDT (p < 
0.001) compared to HC data (Table 2). Patients who responded as not feeling 
numbness, did not differ in their mechanical detection sensitivity compared to HC 
data. 
 
Sensitivity to slight pressure 
Patients responding being sensitive to pressure demonstrated significantly increased 
pressure sensitivity compared to HC (p = 0.004) and to patients responding not being 
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sensitive to pressure (p < 0.001) (Table 2). Patients reporting not being sensitive did 
not differ compared to HC. 
 
3.2.2. Patients with fibromyalgia 
Sensitivity to light touch 
The PD-Q report indicated sensitivity to light touch in four patients with FM (Table 
3), and none of these patients demonstrated DMA on QST testing. Eighteen patients 
reported not being sensitive to light touch on PD-Q. Three of these patients 
demonstrated DMA on QST testing.  
 
Sensitivity to cold/heat 
Regardless of PD-Q responses to cold/heat sensitivity, all patients with FM 
demonstrated a significantly increased sensitivity to both thermal stimuli (p < 0.001) 
(Table 3). There was no significant difference in CPT and HPT between patients 
responding on PD-Q as being sensitive to these thermal stimuli and those responding 
as not being sensitive. 
 
Sensation of numbness 
Patients responding as feeling numbness in their maximal pain area did not 
demonstrate a significant difference in MDT or VDT compared to HC (Table 3). 
Patients responding as not feeling numbness, demonstrated a loss of sensation with a 
significant difference in VDT (p = 0.008) compared to HC, but not in MDT  





Sensitivity to slight pressure 
All patients with FM demonstrated a significantly increased sensitivity to pressure  
compared to HC, regardless of a positive or negative PD-Q response (positive 
responders: p < 0.001; negative responders: p = 0.017) (Table 3).  
 
3.3. Analyses using a cut-off score > 3 
While the number of patients with CxRAD and patients with FM responding positive 
or negative to the PD-Q differed compared to the analyses using a cut-off score (≥ 3), 
(i.e. less patients responded positive to the item descriptors), the results remain mostly 
consistent with our previous analyses (supplementary material Tables S4, S5). 
Compared to HC, patients with CxRAD who indicated being sensitive to a parameter 
demonstrated the sensory alteration (MDT: p = 0.043; VDT: p = 0.013; PPT: p = 
0.001) (Table S4). Although patients who did not indicate being sensitive to cold or 
feeling numbness also demonstrated the sensory alteration (CPT: p = 0.015; VDT: p = 
0.004) (Table S4), the difference in CPT between these patients and HC was not 
clinically significant. All patients with FM, irrespective of their answers to PD-Q, 
demonstrated increased sensitivity to both thermal and pressure stimuli (positive 
responders: CPT, HPT: p <0.001; PPT: p = 0.002, negative responders: CPT, HPT, 
PPT: p <0.001) and patients who did not indicate feeling numbness in their main area 
of pain, also demonstrated a loss of sensation compared to HC (VDT: p = 0.003) 




We investigated whether the self-reported sensory descriptors of patients with 
CxRAD and patients with FM, obtained through the PD-Q, were associated with the 
corresponding QST parameters, using HC QST data as reference criteria. Patients 
with CxRAD demonstrated a match between their self-reported sensory phenotype 
and their QST sensory phenotype for all sensory descriptors except for sensitivity to 
light touch. In contrast self-reported sensory descriptors did not consistently match 
the QST parameters in patients with FM.  
 
Clinical and QST somatosensory profiles of study groups 
Our patient cohort of CxRAD was characterised predominantly by mechanical 
hypoaesthesia with 83% reporting the presence of numbness and demonstrating 
elevated MDT and VDT. Negative sensory signs are core signs of NeP due to the 
reduction of afferent input caused by a nerve lesion (Hansson, 2002; Jensen and 
Baron, 2003). In contrast only 16% of patients with painful lumbar 
radiculopathy/radicular pain (Mahn et al., 2011) reported numbness. While this 
difference is partly related to using different cut-off scores for PD-Q, the latter study 
did not employ specific inclusion criteria of nerve root dysfunction, hence it is 
possible that patients may have presented with radicular pain, but without any 
associated nerve damage (Merskey and Bogduk, 1994).  
 
Thermal and mechanical hyperalgesia were present only in a minority of patients with 
CxRAD. Five patients demonstrated cold hyperalgesia defined as ≥ 15° (Bennett, 
2006) which is a common sequel of peripheral nerve injury (de Medinaceli et al., 
1997; Kleggetveit and Jørum, 2010; Landerholm et al., 2010; Taylor et al., 2010) and 
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has been previously demonstrated in patients with CxRAD using QST (Chien et al., 
2008). According to PD-Q results, thermal hyperalgesia was uncommon in patients 
with lumbar radiculopathy/radicular pain (8%) (Mahn et al., 2011). The percentage of 
our patients reporting increased pressure and light touch sensitivity was consistent 
with findings by Mahn et al (2011). Our patients’ somatosensory profile corresponded 
with that of a subset of patients with lumbar radiculopathy/radicular pain (Mahn et al., 
2011), characterised by mainly numbness together with burning pain and 
paraesthesia, indicating deafferentation of the affected skin. Similarly, Maier et al 
(2010) documented in 1236 patients with NeP that for some patients a sensory loss 
was the only presenting sensory abnormality.  
 
The heterogeneity seen in our patient cohort, as indicated by positive or negative 
responders to the PD-Q, may be related to multiple factors, such as the mechanisms 
and magnitude of nerve root compression (e.g. compression due to osteophytic 
stenosis or disc herniation) and symptom duration, and may also reflect the mixed 
pain types (nociceptive/neuropathic) evident in radiculopathies (Baron and Binder, 
2004; Pérez et al., 2007). It has to be mentioned that while the z-score QST profile of 
the CxRAD negative responders did not differ from the HC data and was within one 
standard deviation of the reference data, this does not imply the absence of NeP as 
patients may have responded in the negative for one parameter, but in the positive for 
another.  
 
The demographic features of our FM cohort was consistent with previous data 
(Gormsen et al., 2010). All patients, irrespective of their answers to PD-Q, 
demonstrated increased pressure sensitivity in their maximal pain area, as documented 
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previously using QST (Kosek et al., 1996; Klauenberg et al., 2008; Pfau et al., 2009; 
Blumenstiel et al., 2011) and increased cold/ heat sensitivity, corresponding with 
some QST findings (Kosek et al., 1996; Hurtig et al., 2001; Berglund et al., 2002; 
Blumenstiel et al., 2011), but not with others (Klauenberg et al., 2008; Pfau et al., 
2009). The differences in findings between studies are probably indicative of the 
heterogeneity of FM as sub-groups of patients demonstrating increased thermal 
sensitivity have been identified (Hurtig et al., 2001; Rehm et al., 2010; Koroschetz et 
al., 2011). Our patient cohort might have incorporated a larger proportion of patients 
characterised by increased thermal sensitivity (Rehm et al., 2010; Koroschetz et al., 
2011) which may also explain the observed magnitude of thermal sensitivity (z-scores 
outside 95% confidence interval of HC data). Despite similarities in symptomatology 
between patients with FM and patients with NeP, such as a gain of function in thermal 
and pressure sensitivity, FM cannot be viewed as a neuropathic pain state according 
to the new definition of neuropathic pain (Jensen et al., 2011). 
 
There was a trend to increased MDT in all patients with FM, but this did not reach 
statistical significance. In comparison to other QST studies, Pfau et al (2009) found 
significantly increased MDT in patients with FM compared to HC, but others did not 
(Kosek et al., 1996; Blumenstiel et al., 2011). In this regard, tactile hypoaesthesia 
does not necessarily indicate structural damage to tactile pathways (Geber et al., 
2008) and can be present in clinical pain disorders possibly consistent with changes in 
central nervous system plasticity. Hypoaesthesia was also documented by an 
increased VDT in patients who indicated not feeling numbness. It is unclear why this 




The percentage of our patients indicating numbness (14%), pressure (50%) and 
thermal sensitivity (23%) was lower compared to other studies (numbness 20%-22%, 
pressure sensitivity 50%-83%, thermal sensitivity 26%-54%) (Amris et al., 2010; 
Rehm et al., 2010; Koroschetz et al., 2011). Similarly, a small proportion of our 
patients demonstrated DMA (14%), consistent with findings in another QST study 
(Pfau et al., 2009), but differing to others (20%-28%) (Amris et al., 2010; Rehm et al., 
2010; Blumenstiel et al., 2011; Koroschetz et al., 2011). These differences, together 
with the above mentioned differences in QST findings in patients with FM, may 
provide further support for the presence of sub-groups in this population. 
 
Correspondence between PD-Q sensory descriptors and QST parameters 
The self-reported sensory descriptors of patients with CxRAD corresponded with the 
QST parameters for all sensory descriptors, except for DMA. Compared to HC, 
patients who indicated sensitivity to a specific sensory parameter also demonstrated 
the corresponding sensory alteration. Patients who did not indicate being sensitive to a 
parameter did not demonstrate a sensory alteration. In contrast, self-reported sensory 
descriptors in the FM group did not consistently match the QST parameters. Although 
all patients who indicated sensitivity to heat/cold and pressure demonstrated increased 
sensitivity for these parameters, those who responded as not being sensitive also 
showed these sensory alterations. Furthermore, compared to HC, patients with FM 
who indicated numbness in the area of their pain did not demonstrate significant 
hypoaesthesia. Patients who reported not feeling numbness had a significantly 
elevated VDT, again demonstrating a discrepancy between patients’ self-reported 
profile and the associated QST sensory profile. Our data suggest that there is potential 
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for misclassification if only patient reported outcomes are used for sub-grouping of 
the FM population.  
 
It is unclear why the multiple discrepancies between self-reported and QST 
parameters were observed in patients with FM, but not in patients with CxRAD. The 
observation may suggest a more globally impaired sensory discriminative function in 
the FM cohort. In interpreting our findings, consideration should be given to the fact 
that PD-Q has never been validated for use in the FM population. It is also possible 
that psychological factors (Giesecke et al., 2003) or altered cognitive function (Dick 
et al., 2008) may have influenced patients’ responses to PD-Q. In addition, it is open 
to debate if the PD-Q is suitable for people with widespread pain (Bouhassira and 
Attal, 2011; Mulvey and McBeth, 2011). Although the main pain area was identified 
prior to completing the PD-Q, most of the patients with FM (n = 20) drew their main 
pain area, plus additional pain areas on the PD-Q body chart. It is therefore possible 
that patients answered the questions of verbal descriptors for all their pain areas. It is 
unclear if the indication of multiple pain areas on the body chart could explain the 
discrepancy between patients’ perception of sensory stimuli and the associated QST 
findings, as QST parameters were only measured in the maximal pain area. In 
contrast, all patients with CxRAD indicated correctly the area of their neck-arm 
pain/paraesthesia and also demonstrated good agreement between self-reported and 
QST sensory parameters. 
 
The sample size of our cohorts was small, hence limiting the generalisability of our 
results. However, the recruitment of patients with CxRAD proved to be extremely 
difficult with only 23 fulfilling the inclusion criteria for CxRAD out of 464 clinically 
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examined patients with neck-arm pain. Furthermore, we were not able to gender 
match HC and patient data, however our results were controlled for gender. Our 
preliminary data provide valuable information into the criterion validity of specific 
sensory descriptors of the PD-Q and may direct future research in this field. 
 
In conclusion, the data from our study demonstrate correspondence between the self-
reported sensory descriptors of patients with CxRAD and their associated QST 
parameter. The QST sensory phenotype of patients with FM was not consistently 
reflected by responses to verbal descriptors from the PD-Q. Clinicians and researchers 
should be cautious about relying on PD-Q as a stand-alone screening tool to 




This study was supported by the National Health and Medical Research Council 
(Grant 425560), Arthritis Australia (Victorian Ladies' Bowls Association Grant) and 
the Physiotherapy Research Foundation (seeding grant). We would like to thank Toby 
Hall and Gabriel Lee for their assistance in validation of patients’ diagnosis of 
cervical radiculopathy. We thank Walter Magerl, Thomas Klein and Doreen Pfau 
from the DFNS group for their assistance with implementation of and valuable advice 
on QST. We are grateful to all patients participating in this research and to all 







Brigitte Tampin takes responsibility for the integrity of the work as a whole, from 
inception to published article. Each author contributed to the conception and design of 
the study and analysis and interpretation of data. All authors were involved in the 
drafting and revision of the article, discussed the results and gave final approval of the 




Amris, K., Jespersen, A., Bliddal, H. (2010). Self-reported somatosensory symptoms 
of neuropathic pain in fibromyalgia and chronic widespread pain correlate with tender 
point count and pressure-pain thresholds. Pain 151,664-669. 
Attal, N., Fermanian, C., Fermanian, J., Lantéri-Minet, M., Alchaar, H., Bouhassira, 
D. (2008). Neuropathic pain: Are there distinct subtypes depending on the aetiology 
or anatomical lesion? Pain 138,343-353. 
Baron, R. (2006). Mechanisms of disease: neuropathic pain - a clinical perspective. 
Nat Clin Pract Neurol 2,95-106. 
Baron, R., Binder, A. (2004). How neuropathic is sciatica? The mixed pain concept. 
Orthopäde 33,568-575. 
Baron, R., Tölle, T.R., Gockel, U., Brosz, M., Freynhagen, R. (2009). A cross-
sectional cohort survey in 2100 patients with painful diabetic neuropathy and 
postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain 
146,34-40. 
Bennett, G.J. (2006). Can we distinguish between inflammatory and neuropathic 
pain? Pain Res Manag 11,11-15. 
Berglund, B., Harju, E.-L., Kosek, E., Lindblom, U. (2002). Quantitative and 
qualitative perceptual analysis of cold dysesthesia and hyperalgesia in fibromyalgia. 
Pain 96,177-187. 
Blankenburg, M., Boekens, H., Hechler, T., Maier, C., Krumova, E., Scherens, A., 
Magerl, W., Aksu, F., Zernikow, B. (2010). Reference values for quantitative sensory 
testing in children and adolescents: Developmental and gender differences of 
somatosensory perception. Pain 149,76-88. 
 
28 
Blumenstiel, K., Gerhardt, A., Rolke, R., Bieber, C., Tesarz, J., Friederich, H.-C., 
Eich, W., Treede, R.-D. (2011). Quantitative sensory testing profiles in chronic back 
pain are distinct from those in fibromyalgia. Clin J Pain 27,682-690. 
Bono, C.M., Ghiselli, G., Gilbert, T.J., Kreiner, D.S., Reitman, C., Summers, J.T., 
Baisden, J.L., Easa, J., Fernand, R., Lamer, T., Matz, P.G., Mazanec, D.J., Resnick, 
D.K., Shaffer, W.O., Sharma, A.K., Timmons, R.B., Toton, J.F. (2011). An evidence-
based clinical guideline for the diagnosis and treatment of cervical radiculopathy from 
degenerative disorders. Spine J 11,64-72. 
Bouhassira, D., Attal, N. (2011). Diagnosis and assessment of neuropathic pain: The 
saga of clinical tools. Pain 152,S74-S83. 
Bouhassira, D., Attal, N., Fermanian, J., Alchaar, H., Gautron, M., Masquelier, E., 
Rostaing, S., Lantéri-Minet, M., Collin, E., Grisart, J., Boureau, F. (2004). 
Development and validation of the Neuropathic Pain Symptom Inventory. Pain 
108,248-257. 
Chien, A., Eliav, E., Sterling, M. (2008). Whiplash (Grade II) and cervical 
radiculopathy share a similar sensory presentation: An investigation using quantitative 
sensory testing. Clin J Pain 24,595-603. 
Cruccu, G., Sommer, C., Anand, P., Attal, N., Baron, R., Garcia-Larrea, L., Haanpää, 
M., Jensen, T.S., Serra, J., Treede, R.D. (2010). EFNS guidelines on neuropathic pain 
assessments: revised 2009. Eur J Neurol 17,1010-1018. 
De Andrés, J.M.D.P.F., Pérez-Cajaraville, J.M.D., Lopez-Alarcón, M.D.M.D., López-
Millán, J.M.M.D., Margarit, C.M.D., Rodrigo-Royo, M.D.M.D., Franco-Gay, 
M.L.M.D., Abejón, D.M.D., Ruiz, M.A.P., López-Gomez, V.P., Pérez, M.M.D.P. 
(2012). Cultural adaptation and validation of the painDETECT scale into Spanish. 
Clin J Pain 28,243-253. 
 
29 
de Medinaceli, L., Hurpeau, J.C., Merle, M., Begorre, H. (1997). Cold and post-
traumatic pain: modeling of the peripheral nerve message. Biosystems 43,145-167. 
Dick, B.D., Verrier, M.J., Harker, K.T., Rashiq, S. (2008). Disruption of cognitive 
function in Fibromyalgia Syndrome. Pain 139,610-616. 
Dworkin, R.H., Turk, D.C., Peirce-Sandner, S., Burke, L.B., Farrar, J.T., Gilron, I., 
Jensen, M.P., Katz, N.P., Raja, S.N., Rappaport, B.A., Rowbotham, M.C., Backonja, 
M.-M., Baron, R., Bellamy, N., Bhagwagar, Z., Costello, A., Cowan, P., Fang, W.C., 
Hertz, S., Jay, G.W., Junor, R., Kerns, R.D., Kerwin, R., Kopecky, E.A., Lissin, D., 
Malamut, R., Markman, J.D., McDermott, M.P., Munera, C., Porter, L., Rauschkolb, 
C., Rice, A.S.C., Sampaio, C., Skljarevski, V., Sommerville, K., Stacey, B.R., 
Steigerwald, I., Tobias, J., Trentacosti, A.M., Wasan, A.D., Wells, G.A., Williams, J., 
Witter, J., Ziegler, D. (2012). Considerations for improving assay sensitivity in 
chronic pain clinical trials: IMMPACT recommendations. Pain 153,1148-1158. 
Freynhagen, R., Baron, R., Gockel, U., Tölle, T.R. (2006). painDETECT: A new 
screening questionnaire to identify neuropathic components in patients with back 
pain. Curr Med Res Opin 22,1911-1920. 
Freynhagen, R., Rolke, R., Baron, R., Tölle, T.R., Rutjes, A.-K., Schu, S., Treede, R.-
D. (2008). Pseudoradicular and radicular low-back pain - A disease continuum rather 
than different entities. Answers from quantitative sensory testing. Pain 135,65-74. 
Geber, C., Klein, T., Azad, S., Birklein, F., Gierthmühlen, J., Huge, V., Lauchart, M., 
Nitzsche, D., Stengel, M., Valet, M., Baron, R., Maier, C., Tölle, T., Treede, R.-D. 
(2011). Test-retest and interobserver reliability of quantitative sensory testing 
according to the protocol of the German Research Network on Neuropathic Pain 
(DFNS): A multi-centre study. Pain 152,548-556. 
 
30 
Geber, C., Magerl, W., Fondel, R., Fechir, M., Rolke, R., Vogt, T., Treede, R.-D., 
Birklein, F. (2008). Numbness in clinical and experimental pain - A cross-sectional 
study exploring the mechanisms of reduced tactile function. Pain 139,73-81. 
Giesecke, T., Williams, D.A., Harris, R.E., Cupps, T.R., Tian, X., Tian, T.X., 
Gracely, R.H., Clauw, D.J. (2003). Subgrouping of fibromyalgia patients on the basis 
of pressure-pain thresholds and psychological factors. Arthritis Rheum 48,2916-2922. 
Gormsen, L., Rosenberg, R., Bach, F.W., Jensen, T.S. (2010). Depression, anxiety, 
health-related quality of life and pain in patients with chronic fibromyalgia and 
neuropathic pain. Eur J Pain 14,127.e121-127.e128. 
Gwilym, S.E., Keltner, J.R., Warnaby, C.E., Carr, A.J., Chizh, B., Chessell, I., 
Tracey, I. (2009). Psychophysical and functional imaging evidence supporting the 
presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Care 
Res 61,1226-1234. 
Haanpää, M., Attal, N., Backonja, M., Baron, R., Bennett, M., Bouhassira, D., 
Cruccu, G., Hansson, P., Haythornthwaite, J.A., Iannetti, G.D., Jensen, T.S., 
Kauppila, T., Nurmikko, T.J., Rice, A.S.C., Rowbotham, M., Serra, J., Sommer, C., 
Smith, B.H., Treede, R.-D. (2011). NeuPSIG guidelines on neuropathic pain 
assessment. Pain 152,14-27. 
Hallström, H., Norrbrink, C. (2011). Screening tools for neuropathic pain: Can they 
be of use in individuals with spinal cord injury? Pain 152,772-779. 
Hansson, P. (2002). Neuropathic pain: clinical characteristics and diagnostic workup. 
Eur J Pain 6,47-50. 
Hansson, P., Backonja, M., Bouhassira, D. (2007). Usefulness and limitations of 
quantitative sensory testing: Clinical and research application in neuropathic pain 
states. Pain 129,256-259. 
 
31 
Hurtig, I.M., Raak, R.I., Kendall, S.A., Gerdle, B., Wahren, L.K. (2001). Quantitative 
sensory testing in fibromyalgia patients and in healthy subjects: identification of 
subgroups. Clin J Pain 17,316-322. 
Jensen, M., Karoly, P., O’Riordan, E., Bland, F., Burns, R. (1989). The subjective 
experience of acute pain. An assessment of the utility of ten indices. Clin J Pain 
5,153-159. 
Jensen, T.S., Baron, R. (2003). Translation of symptoms and signs into mechanisms 
in neuropathic pain. Pain 102,1-8. 
Jensen, T.S., Baron, R., Haanpää, M., Kalso, E., Loeser, J.D., Rice, A.S.C., Treede, 
R.-D. (2011). A new definition of neuropathic pain. Pain 152,2204-2205  
Jespersen, A., Amris, K., Bliddal, H. (2010). Is neuropathic pain underdiagnosed in 
musculoskeletal pain conditions? The Danish PainDETECTive study. Curr Med Res 
Opin 26,2041-2045. 
Klauenberg, S., Maier, C., Assion, H.-J., Hoffmann, A., Krumova, E.K., Magerl, W., 
Scherens, A., Treede, R.-D., Juckel, G. (2008). Depression and changed pain 
perception: Hints for a central disinhibition mechanism. Pain 140,332-343. 
Kleggetveit, I.P., Jørum, E. (2010). Large and small fiber dysfunction in peripheral 
nerve injuries with or without spontaneous pain. J Pain 11,1305-1310. 
Koroschetz, J., Rehm, S.E., Gockel, U., Brosz, M., Freynhagen, R., Tölle, T.R., 
Baron, R. (2011). Fibromyalgia and neuropathic pain - differences and similarities. A 
comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC 
Neurol 11. 
Kosek, E., Ekholm, J., Hansson, P. (1996). Sensory dysfunction in fibromyalgia 
patients with implications for pathogenic mechanism. Pain 68,375-383. 
 
32 
Landerholm, Å.H., Ekblom, A.G., Hansson, P.T. (2010). Somatosensory function in 
patients with and without pain after traumatic peripheral nerve injury. Eur J Pain 
14,847-853. 
Mahn, F., Hüllemann, P., Gockel, U., Brosz, M., Freynhagen, R., Tölle, T.R., Baron, 
R. (2011). Sensory symptom profiles and co-morbidities in painful radiculopathy. 
PLoS One 6,e18018. 
Maier, C., Baron, R., Tölle, T.R., Binder, A., Birbaumer, N., Birklein, F., 
Gierthmühlen, J., Flor, H., Geber, C., Huge, V., Krumova, E.K., Landwehrmeyer, 
G.B., Magerl, W., Maihöfner, C., Richter, H., Rolke, R., Scherens, A., Schwarz, A., 
Sommer, C., Tronnier, V., Üçeyler, N., Valet, M., Wasner, G., Treede, R.-D. (2010). 
Quantitative sensory testing in the German Research Network on Neuropathic Pain 
(DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic 
pain syndromes. Pain 150,439-450. 
Merskey, H., Bogduk, N. (1994). Classification of chronic pain. Seattle: IASP Press. 
Mulvey, M.R., McBeth, J. (2011). Comment on: "Self-reported somatosensory 
symptoms of neuropathic pain in fibromyalgia and chronic widespread pain correlated 
with tender point count and pressure-pain thresholds" by Amris et al. [Pain;151:664-
669]. Pain 152,1684-1685. 
Pérez, C., Galvez, R., Huelbes, S., Insausti, J., Bouhassira, D., Diaz, S., Rejas, J. 
(2007). Validity and reliability of the Spanish version of the DN4 (Douleur 
Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes 
associated to a neuropathic or somatic component. Health Qual Life Outcomes 5. 
Pfau, D.B., Rolke, R., Nickel, R., Treede, R.D., Daublaender, M. (2009). 
Somatosensory profiles in subgroups of patients with myogenic temporomandibular 
disorders and fibromyalgia syndrome. Pain 147,72-83. 
 
33 
Rehm, S.E., Koroschetz, J., Gockel, U., Brosz, M., Freynhagen, R., Tölle, T.R., 
Baron, R. (2010). A cross-sectional survey of 3035 patients with fibromyalgia: 
subgroups of patients with typical comorbidities and sensory symptom profiles. 
Rheumatology (Oxford) 49,1146-1152. 
Rolke, R., Baron, R., Maier, C., Tölle, T.R., Treede, R.-D., Beyer, A., Binder, A., 
Birbaumer, N., Birklein, F., Bötefür, I.C., Braune, S., Flor, H., Huge, V., Klug, R., 
Landwehrmeyer, G.B., Magerl, W., Maihöfner, C., Rolko, C., Schaub, C., Scherens, 
A., Sprenger, T., Valet, M., Wasserka, B. (2006a). Quantitative sensory testing in the 
German Research Network on Neuropathic Pain (DFNS): Standardized protocol and 
reference values. Pain 123,231-243. 
Rolke, R., Magerl, W., Campbell, K.A., Schalber, C., Caspari, S., Birklein, F., 
Treede, R.D. (2006b). Quantitative sensory testing: a comprehensive protocol for 
clinical trials. Eur J Pain 10,77-88. 
Steegers, M.A.H., Snik, D.M., Verhagen, A.F., van der Drift, M.A., Wilder-Smith, 
O.H.G. (2008). Only half of the chronic pain after thoracic surgery shows a 
neuropathic component. J Pain 9,955-961. 
Taylor, K.S., Anastakis, D.J., Davis, K.D. (2010). Chronic pain and sensorimotor 
deficits following peripheral nerve injury. Pain 151,582-591. 
Treede, R.-D., Jensen, T.S., Campbell, J.N., Cruccu, G., Dostrovsky, J.O., Griffin, 
J.W., Hansson, P., Hughes, R., Numikko, T., Serra, J. (2008). Neuropathic pain. 
Redifinition and a grading system for clinical and research purposes. Neurology 
70,1630-1635. 
Ware, J.E. (2000). SF-36 Health Survey update. Spine 25,3130-3139. 
Wolfe, F., Clauw, D.J., Fitzcharles, M.A., Goldenberg, D.L., Katz, R.S., Mease, P., 
Russell, A.S., Russel, I.J., Winfield, J.B., Yunus, M.P. (2010). The American College 
 
34 
of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of 
symptom severity. Arthritis Care Res 62,600-610. 
Wolfe, F., Smythe, H.A., Yunus, M.B., Bennet, R.M., Bombardier, C., Goldenberg, 
D.L., Tugwell, P., Campbell, S.M., Abeles, M., Clark, P., Fam, A.G., Farber, S.J., 
Feiechtner, J.J., Franklin, C.M., Gatter, R.A., Hamaty, D., Lessard, J., Lichtbroun, 
A.S., Masi, A.T., McCain, G.A., Reynolds, W.J., Romano, T.J., Russell, U., Sheon, 
R.P. (1990). The American College of Rheumatology 1990 Criteria for the 
classification of fibromyalgia. Arthritis Rheum 33,160-172. 
Zigmond, A.S., Snaith, R.P. (1983). The Hospital Anxiety and Depression Scale. Acta 




Table 1  
Demographics and profiles of healthy control (HC) subjects, patients with cervical radiculopathy (CxRAD) and  
patients with fibromyalgia (FM)  
 HC  
(n = 31) 
CxRAD  
(n = 23) 
FM  
(n = 22) 
p-value 
 
Age (years)f 45.6 (12.5) 46.3 (9.6) 46.1 (11.5) 0.968 
Gender (female, n) 15 8 20  
Symptom duration (months)f  7.6 (4.1) 124.9 (83.1) <0.001 
Average pain intensity during last week (VAS)f  5.2 (2.0) 7.3 (1.2) <0.001 
Maximal pain intensity during last 4 weeks (NRS 0-10)f  7.2 (2.2) 8.3 (1.2) 0.054 
Average pain intensity during last 4 weeks (NRS 0-10)f  5.0 (2.1) 6.2 (1.3) 0.025 
Sleep quality during last week (VAS)f  2.9 (2.6) 5.3 (2.7)b 6.8 (2.3)a <0.001 



























Hospital Anxiety and Depression Scale    
Anxiety score (HADS)g 3.0 (5.0) 6.0 (5.0)b 12.0 (6.2)a, c <0.001 
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Within normal range (≤ 10), n  29 (93%) 21(91%) 7 (32%)  
Depression score (HADS)g 1.0 (1.0) 3.0 (4.0)a 6.0 (4.2)a, d <0.001 
Within normal range (≤ 10), n  31 (100%) 21 (91%) 19 (86%)  
SF-36     
Physical Componentg 57.7 (3.7) 40.6 (12.6)a 36.4 (11.9)a,  <0.001 
Mental Componentg 56.0 (7.6) 52.3 (17.4)b 30.8 (21.5)a, d <0.001 
     
Patients with medication, n   15 (65.2%) 12 (54.5%)  
Current medicatione     
Selective serotonin reuptake inhibitor, n   1 (4.3%) 7 (31.8%)  
Serotonin-norepinephrine reuptake inhibitor, n  2 (8.7%) 2 (9.1%)  
Tricyclic antidepressant, n  1 (4.3%) 3 (13.6%)  
Tetracyclic antidepressant, n   1 (4.5%)  
Antiepileptics, n  2 (8.7%)   
Opioids, n  4 (17.4%) 1 (4.5%)  
Benzodiazepine, n  2 (8.7%)   
Analgesics, n  7 (30.4%) 3 (13.6%)  
Non-steroidal anti-inflammatories, n  7 (30.4%)   
aSignificantly different to HC (p < 0.001).  
bSignificantly different to HC (p < 0.05).  
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cSignificantly different to CxRAD (p < 0.001). 
dSignificantly different to CxRAD (p < 0.05). 
eMultiple answers possible. 
fData are mean (SD)  




Table 2  
Comparison of each QST parameter between healthy controls (HC), patients with  
cervical radiculopathy (CxRAD) who responded on painDETECT as being sensitive  
to a QST parameter (positive), and patients who responded on painDETECT as  
being not sensitive to a QST parameter (negative). The score “moderate” was used  
as the cut-off score for answers on the painDETECT. Data are shown as mean (SD)  
for untransformed data and retransformed mean for log-normally distributed data 
(CPT, MDT, PPT). 
 HC  






Is light touching in this 
area painful?  
 n = 4 n = 19  
DMA 0 had DMA 1 had DMA 0 had DMA  
Is cold or heat in this area 
occasionally painful? 
 n = 5 n = 18  
CPT (°C) 7.0  18.8a 9.6  0.001 
HPT (°C) 46.7 (1.9) 41.2 (5.6)a, b 46.5 (3.3) 0.003 
Do you suffer from a  
sensation of numbness in  
the area that you marked? 
 n = 19 n = 4 
 
MDT (mN) 1.9  4.5a  1.7 0.006 
VDT (x/8) 6.1 (0.9) 5.3 (1.2)a 5.8 (0.2) 0.002 
Does slight pressure in 
this area trigger pain? 
 n = 7 n = 16  
PPT (kPa) 439  303a, c  457  0.001 
DMA: dynamic mechanical allodynia, CPT: cold pain threshold, HPT: heat pain 
threshold, MDT: mechanical detection threshold, VDT: vibration threshold, PPT: 
pressure pain threshold. 
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aSignificantly different to HC (p < 0.05). 
bSignificantly different to CxRAD negative (p < 0.05).  




Table 3  
Comparison of each QST parameter between healthy controls (HC), patients with 
fibromyalgia (FM) who responded on painDETECT as being sensitive to a QST  
parameter (positive), and patients who responded on painDETECT as being not  
sensitive to a QST parameter (negative). The score “moderate” was used as the 
cut-off score for answers on the painDETECT. Data are shown as mean (SD) for  
untransformed data and retransformed mean for log-normally distributed data  
(CPT, MDT, PPT). 
 HC  







Is light touching in this 
area painful?  
 n = 4 n = 18  
DMA 0 had DMA 0 had DMA 3 had DMA  
Is cold or heat in this area 
occasionally painful? 
 n = 10 n = 12 
 
CPT (°C) 7.0  21.9a 26.3a <0.001 
HPT (°C) 46.7 (1.9) 39.2 (3.2)a 39.8 (3.5)a <0.001 
Do you suffer from a  
sensation of numbness in  
the area that you marked? 
 n = 7 n = 15 
 
MDT (mN) 1.9  2.9 3.2 0.208 
VDT (x/8) 6.1 (0.9) 6.1 (1.1) 5.2 (1.0)b 0.010 
Does slight pressure in 
this area trigger pain? 
 n = 18 n = 4  
PPT (kPa) 439  182a 186b <0.001 
DMA: dynamic mechanical allodynia, CPT: cold pain threshold, HPT: heat pain 
threshold, MDT: mechanical detection threshold, VDT: vibration threshold, PPT: 
pressure pain threshold. 
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aSignificantly different to HC (p < 0.001).  
bSignificantly different to HC (p < 0.05). 
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Table S4  
Comparison of each QST parameter between healthy controls (HC), patients with  
cervical radiculopathy (CxRAD) who responded on painDETECT as being  
sensitive to a QST parameter (positive), and patients who responded on  
painDETECT as being not sensitive to a QST parameter (negative). The score  
“strongly” was used as the cut-off score for answers on the painDETECT. Data are 
shown as mean (SD) for untransformed data and retransformed mean for  
log-normally distributed data (CPT, MDT, PPT). 
 HC  






Is light touching in this  
area painful? 
 n = 0 n = 23  
DMA 0 had DMA 0 had DMA 1 had DMA   
Is cold or heat in this area 
occasionally painful?  n = 1 n = 22 
 
CPT (°C) 7.0 26.2 10.7bd  
HPT (°C) 46.7 (1.9) 36.6 45.8 (4.0)d  
Do you suffer from a  
sensation of numbness in  
the area that you marked? 
 n = 11 n = 12 
 
MDT (mN) 1.9 4.5b 3.3 0.012 
VDT (x/8) 6.1 (0.9) 5.4 (1.2)b 5.4 (1.1)b 0.004 
Does slight pressure in 
this area trigger pain?  n = 5 n = 18 
 
PPT (kPa) 439 335b, c 424 <0.001 
DMA: dynamic mechanical allodynia, CPT: cold pain threshold, HPT: heat pain  
threshold, MDT: mechanical detection threshold, VDT: vibration threshold, PPT:  
pressure pain threshold.  
aSignificantly different to HC (p < 0.001). 
bSignificantly different to HC (p < 0.05). 




Table S5  
Comparison of each QST parameter between healthy controls (HC), patients with  
fibromyalgia (FM) who responded on painDETECT as being sensitive to a QST  
parameter (positive), and patients who responded on painDETECT as being not  
sensitive to a QST parameter (negative). The score “strongly” was used as the 
cut-off score for answers on the painDETECT. Data are shown as mean (SD) for 
untransformed data and retransformed mean for log-normally distributed data  
(CPT, MDT, PPT). 
 HC  






Is light touching in this  
area painful? 
 n = 1 n = 21  
DMA 0 had DMA 0 had DMA 3 had DMA   
Is cold or heat in this area 
occasionally painful? 
 n = 5 n = 17 
 
CPT (°C) 7.0 17.4a 29.0a, c < 0.001 
HPT (°C) 46.7 (1.9) 40.5 (3.6)a 39.2 (3.3)a < 0.001 
Do you suffer from a  
sensation of numbness in  
the area that you marked? 
 n = 3 n = 19 
 
MDT (mN) 1.9 7.1 2.7d  
VDT (x/8) 6.1 (0.9) 6.6 (0.8) 5.3 (1.1)b, d  
Does slight pressure in 
this area trigger pain? 
 n = 11 n = 11  
PPT (kPa) 439 201b 167a < 0.001 
DMA: dynamic mechanical allodynia, CPT: cold pain threshold, HPT: heat pain  
threshold, MDT: mechanical detection threshold, VDT: vibration threshold, PPT:  
pressure pain threshold. 
 
44 
aSignificantly different to HC (p < 0.001). 
































































Fig. 1. Sensory profiling of patients with cervical radiculopathy (CxRAD). The z-score sensory 
profiles are shown for cold pain threshold (CPT), heat pain thresholds (HPT), mechanical 
detection threshold (MDT), vibration detection threshold (VDT), pressure pain threshold (PPT) 
in patients responding positive (filled square) and negative to verbal descriptors (empty 
triangle). Data are shown as the mean. The score “moderate” was used as the cut-off score for 
answers on the painDETECT. 





















































Fig. 2. Sensory profiling of patients with fibromyalgia (FM). The z-score sensory profiles are 
shown for cold pain threshold (CPT), heat pain thresholds (HPT), mechanical detection 
threshold (MDT), vibration detection threshold (VDT), pressure pain threshold (PPT) in patients 
responding positive (filled square) and negative to verbal descriptors (empty triangle). Data are 
shown as the mean. The score “moderate” was used as the cut-off score for answers on the 
painDETECT. 
*Significantly different from HC (p < 0.05). 
**Significantly different from HC (p < 0.001). 
 
 
